Stockscreener 앱 받기
2.31
3.75%
-0.09
시간 외 거래:
2.32
0.010
+0.43%
Black Diamond Therapeutics Inc 주식(BDTX)의 최신 뉴스
Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise - MSN
Black Diamond Therapeutics Reports Strong Financial Turnaround - TipRanks
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Cuts Target Price to $10 - 富途牛牛
H.C. Wainwright lowers Black Diamond Therapeutics stock price target on delayed launch - Investing.com Canada
Published on: 2025-08-11 06:28:53 - Newser
News impact scoring models applied to Black Diamond Therapeutics Inc.Fundamental Forecast for Undervalued Stocks - Newser
When is the best time to exit Black Diamond Therapeutics Inc.Momentum Trend Signal Weekly Recap Summary - Newser
Chart based analysis of Black Diamond Therapeutics Inc. trendsEquity Portfolio Outlook and Performance Summary - Newser
Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance
Historical volatility pattern of Black Diamond Therapeutics Inc. visualizedFree Daily Chart Pattern Stock Forecast - Newser
Black Diamond Therapeutics Slims Losses And Stays Flush With Cash - Finimize
Black Diamond (BDTX) Q2 Loss Narrows 47% - AOL.com
Black Diamond Therapeutics: Navigating Turbulent Waters with Strategic Precision - AInvest
Top Risks to Consider Before Buying Black Diamond Therapeutics Inc. StockMulti-Year Signal Summary and Entry Timing - Newser
Black Diamond Therapeutics Cuts Losses And Eyes Silevertinib Growth - Finimize
Black Diamond: Q2 Earnings Snapshot - The Washington Post
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Black Diamond Therapeutics Q2 Loss Narrower Than ExpectedNews and Statistics - IndexBox
Black Diamond Therapeutics Q2 eps $-0.19 - MarketScreener
Black Diamond (BDTX) Q2 Loss Narrows 47% - The Motley Fool
Black Diamond Therapeutics Completes Enrollment in Phase 2 Trial of Silevertinib for Non-Classical EGFRm NSCLC - Quiver Quantitative
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Black Diamond Therapeutics, Inc. SEC 10-Q Report - TradingView
What makes Black Diamond Therapeutics Inc. stock price move sharplyFundamental + Technical Combined Watchlist - Newser
Will Black Diamond Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsFree Daily Top Performing Stock Insights - Newser
Why Black Diamond Therapeutics Inc. stock attracts strong analyst attentionFree Investment Playbook for Growing Markets - Newser
Price action breakdown for Black Diamond Therapeutics Inc.Daily Profit Watch With Forecast Confidence - Newser
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Rating of “Buy” by Brokerages - Defense World
Is Black Diamond Therapeutics Inc. stock ready for a breakoutHigh Return Idea With Technical Filter - Newser
Is Black Diamond Therapeutics Inc. a Top Dividend Stock to Watch in 2025Short-Term Market Movement Forecast Report - Newser
Using portfolio simulators with Black Diamond Therapeutics Inc. includedReal-Time Entry Forecast with Accuracy Metrics - Newser
Has Black Diamond Therapeutics Inc. formed a bullish divergenceFree AI Screening for Swing Trade Picks - Newser
Competitive Positioning of Black Diamond Therapeutics Inc.: Is It Leading or LaggingDaily Swing Candidate Analysis with Chart Patterns - Newser
What institutional investors are buying Black Diamond Therapeutics Inc. stockMaximize your portfolio’s earning potential - Jammu Links News
Is Black Diamond Therapeutics Inc. stock overvalued or undervaluedExponential return rates - Jammu Links News
What is Black Diamond Therapeutics Inc. company’s growth strategySuperior investment outcomes - Jammu Links News
How does Black Diamond Therapeutics Inc. generate profit in a changing economyGet daily expert analysis on top stocks - Jammu Links News
What are Black Diamond Therapeutics Inc. company’s key revenue driversCapitalize on emerging investment opportunities - Jammu Links News
What analysts say about Black Diamond Therapeutics Inc. stockHarness the power of proven investment plans - Jammu Links News
Automated trading signals detected on Black Diamond Therapeutics Inc.Monthly Trade Result and Signal Summary - Newser
How volatile is Black Diamond Therapeutics Inc. stock compared to the marketFind the best stocks for sustainable growth - Jammu Links News
How strong is Black Diamond Therapeutics Inc. company’s balance sheetAchieve rapid portfolio appreciation today - Jammu Links News
Black Diamond Therapeutics Inc. Stock Analysis and ForecastInvest smarter with data-backed trading alerts - Jammu Links News
1.02%
3.70%
자본화:
|
볼륨(24시간):